Q32 Bio (Q32 Bio) Pretax Margin % : % (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Q32 Bio's Pre-Tax Income for the three months ended in Mar. 2024 was $1.21 Mil. Q32 Bio's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Q32 Bio's pretax margin for the quarter that ended in Mar. 2024 was %.

The historical rank and industry rank for Q32 Bio's Pretax Margin % or its related term are showing as below:

QTTB' s Pretax Margin % Range Over the Past 10 Years
Min: -642.72 Med: 80.27 Max: 803.26
Current: 174.66

QTTB's Pretax Margin % is ranked better than
98.05% of 1027 companies
in the Biotechnology industry
Industry Median: -154.52 vs QTTB: 174.66

Q32 Bio Pretax Margin % Historical Data

The historical data trend for Q32 Bio's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio Pretax Margin % Chart

Q32 Bio Annual Data

Trend

Dec21

Dec22

Dec23

Pretax Margin %

-642.72

803.26

Q32 Bio Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Pretax Margin %	Get a 7-Day Free Trial			-255.85	-232.03	-	182.88	-

Competitive Comparison of Q32 Bio's Pretax Margin %

For the Biotechnology subindustry, Q32 Bio's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q32 Bio's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Q32 Bio's Pretax Margin % falls into.

Q32 Bio Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Q32 Bio's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-53.425	/	-6.651
	=	803.26 %

Q32 Bio's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin	=	Pre-Tax Income (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	1.205	/	0
	=	%

Q32 Bio (NAS:QTTB) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Q32 Bio Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Q32 Bio's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Q32 Bio (Q32 Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Pretax Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.q32bio.com

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio (Q32 Bio) Headlines

From GuruFocus

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

By PRNewswire • 04-03-2024